BRAF and melanoma: Vemurafenib was designed and approved to treat melanoma patients with B-RAF V600E mutations; however, although marked responses were initially observed, resistance developed rapidly and presented in the form of more aggressive tumors, or development of secondary malignancies in the context of pre-existing RAS mutations [76,77,78,79].